Skip to main content

Table 2 Clinicopathologic characteristics of patients stratified by both neoadjuvant and adjuvant chemotherapy

From: Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?

Parameters With preoperative chemotherapy (n = 122) P value Without preoperative chemotherapy (n = 142) P value
With ACT (n, %) Without ACT (n, %) With ACT (n, %) Without ACT (n, %)
Number of patients 98 24   102 40  
Age, years
 ≤ 60 69 (70.4) 16 (66.7) 0.721 60 (58.8) 19 (47.5) 0.222
 > 60 29 (29.6) 8 (33.3)   42 (41.2) 21 (52.5)  
Sex
 Male 65 (66.3) 17 (70.8) 0.673 63 (61.8) 26 (65.0) 0.720
 Female 33 (33.7) 7 (29.2)   39 (38.2) 14 (35.0)  
Primary tumor location
 Colon 55 (56.1) 15 (62.5) 0.571 71 (69.6) 22 (55.0) 0.100
 Rectum 43 (43.9) 9 (37.5)   31 (30.4) 18 (45.0)  
Primary tumor differentiation
 Well to moderate 72 (73.5) 20 (83.3) 0.315 83 (81.4) 31 (77.5) 0.602
 Poor 26 (26.5) 4 (16.7)   19 (18.6) 9 (22.5)  
T stagea
 1–3 50 (53.2) 12 (54.5) 0.909 72 (77.4) 23 (67.6) 0.261
 4 44 (46.8) 10 (45.5)   21 (22.6) 11 (32.4)  
N stageb
 0 41 (45.6) 12 (54.5) 0.449 37 (40.2) 13 (38.2) 0.840
 1–2 49 (54.4) 10 (45.5)   55 (59.8) 21 (61.8)  
Timing of metastasis
 Synchronous 74 (75.5) 15 (62.5) 0.198 62 (60.8) 20 (50.0) 0.242
 Metachronous 24 (24.5) 9 (37.5)   40 (39.2) 20 (50.0)  
Number of metastatic tumors
 1 29 (29.6) 9 (37.5) 0.453 73 (71.6) 29 (72.5) 0.912
 2–5 69 (70.4) 15 (62.5)   29 (28.4) 11 (27.5)  
Metastases diameter (cm)c
 ≤ 3 59 (62.1) 14 (58.3) 0.735 75 (73.5) 25 (64.1) 0.270
 > 3 36 (37.9) 10 (41.7)   27 (26.5) 14 (35.9)  
Preoperative CEA (ng/mL)d
 ≤ 50 78 (82.1) 17 (81.0) 0.901 78 (81.3) 27 (69.2) 0.128
 > 50 17 (17.9) 4 (19.0)   18 (18.8) 12 (30.8)  
Preoperative CA19-9 (U/mL)e
 ≤ 35 70 (76.9) 15 (75.0) 1.000 58 (61.1) 23 (62.2) 0.906
 > 35 21 (23.1) 5 (25.0)   37 (38.9) 14 (37.8)  
MSKCC-CRSf
 0–2 54 (63.5) 9 (47.4) 0.193 73 (83.0) 26 (78.8) 0.597
 3–5 31 (36.5) 10 (52.6)   15 (17.0) 7 (21.2)  
Preoperative chemotherapy regimen
 FOLFOX + XELOX 61 (62.2) 18 (75.0) 0.503    
 FOLFIRI 31 (31.6) 5 (20.8)     
 Capecitabine 6 (6.1) 1 (4.2)     
Radiological response to preoperative chemotherapyg
 PR 57 (58.8) 13 (54.2) 0.683    
 SD 30 (30.9) 7 (29.2)     
 PD 10 (10.3) 4 (16.7)     
  1. ACT adjuvant chemotherapy, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, MSKCC-CRS Memorial Sloan-Kettering Cancer Center clinical risk score, PD progressive disease, PR partial response, SD stable disease
  2. aData were available for 243 patients
  3. bData were available for 238 patients
  4. cData were available for 260 patients
  5. dData were available for 251 patients
  6. eData were available for 243 patients
  7. fData were available for 225 patients
  8. gData were available for 121 patients
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us